Bladder Urothelial Carcinoma

Oncology·MeSH: Urinary Bladder Neoplasms

Prevalence

61.0 / 100K

Incidence

18.0 / 100K/yr

19 drugs in development·8 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(10)

Drug	Company
Apalutamide	Crinetics Pharmaceuticals, Inc. (CRNX)
Apalutamide	Myovant Sciences Ltd. (MYOV)
Avelumab	Merus N.V. (MRUS)
Avelumab	Royalty Pharma plc (RPRX)
bcg	GH Research PLC (GHRS)
bcg tokyo-172 strain	GH Research PLC (GHRS)
bcg tokyo-172 strain vaccine	GH Research PLC (GHRS)
Eribulin Mesylate	Arbutus Biopharma Corp (ABUS)
Procarbazine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Sacituzumab Govitecan	Arbutus Biopharma Corp (ABUS)

Phase 2(7)

Drug	Company
Arginine hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Copanlisib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Defactinib Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Eflornithine Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Nilotinib Hydrochloride Monohydrate	ENANTA PHARMACEUTICALS INC (ENTA)
Propranolol Hydrochloride	ENANTA PHARMACEUTICALS INC (ENTA)
Relatlimab	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(2)

Drug	Company
Avelumab	ENANTA PHARMACEUTICALS INC (ENTA)
Enfortumab Vedotin	Fulgent Genetics Inc. (FLGT)

BioSniper tracks 19 drugs in development for Bladder Urothelial Carcinoma across 8 companies.

There are 3 clinical trials targeting Bladder Urothelial Carcinoma tracked by BioSniper.

The estimated prevalence of Bladder Urothelial Carcinoma is approximately 61.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.